Circulating tumor DNA (ctDNA) for informing adjuvant chemotherapy (ACT) in stage II/III colorectal cancer (CRC): Interim analysis of BESPOKE CRC study.

被引：12

作者：

Kasi, Pashtoon Murtaza ^{[1
]}

Aushev, Vasily N. ^{[2
]}

Ensor, Joe ^{[2
]}

Langer, Nathan ^{[3
]}

Wang, Christopher Gene ^{[4
]}

Cannon, Timothy Lewis ^{[5
]}

Berim, Lyudmyla Derby ^{[6
]}

Feinstein, Trevor ^{[7
]}

Grothey, Axel ^{[8
]}

McCollom, Joseph William ^{[9
]}

Kalmadi, Sujith R. ^{[10
]}

Zakari, Ahmed ^{[11
]}

Dayyani, Farshid ^{[12
]}

Gravenor, Donald ^{[13
]}

Meyer, Janelle Marie ^{[14
]}

Sharif, Saima ^{[15
]}

Jurdi, Adham A. ^{[2
]}

Liu, Minetta C. ^{[2
]}

Aleshin, Alexey ^{[2
]}

Kopetz, Scott ^{[16
]}

机构：

[1] NewYork Presbyterian Hosp, Englander Inst Precis Med, Weill Cornell Med, New York, NY USA

[2] Natera Inc, Austin, TX USA

[3] Virginia Canc Inst QCCA, Richmond, VA USA

[4] Alabama Oncol, Birmingham, AL USA

[5] Inova Schar Canc Inst, Fairfax, VA USA

[6] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[7] Piedmont Canc Inst, Atlanta, GA USA

[8] West Canc Ctr, Germantown, TN USA

[9] Parkview Canc Inst, Ft Wayne, IN USA

[10] Ironwood Canc & Res Ctr, Chandler, AZ USA

[11] Adventhlth Canc Inst, Orlando, FL USA

[12] Univ Calif Irvine, Dept Med, Div Hematol Oncol, Orange, CA USA

[13] Baptist Canc Ctr, Memphis, TN USA

[14] Oregon Oncol Specialists, Salem, OR USA

[15] Univ Iowa, Iowa City, IA USA

[16] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期

关键词：

283-237-255; 281-206-4760-6705; 261-376-454; 281-318-9508; 281-318-9493; 261-492-3532-2370-7650-2454; 261-376; 9; 7; 6; 4; 2;

D O I：

10.1200/JCO.2024.42.3_suppl.9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：9 / 9

页数：1

共 50 条

[11] Adjuvant chemotherapy (AC) choices: An analysis of elderly Australian patients with stage III colorectal cancer (CRC)
Piercey, Oliver
Leung, Clara
Lee, Margaret
Tie, Jeanne
Yeung, Justin
McCormick, Jacob
Steel, Malcolm
Heong, Valerie
To, Yat Hang
Gibbs, Peter
Wong, Rachel
Wong, Hui-Li
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[12] A clinical validation study to predict recurrence in stage II-III colorectal cancer (CRC) using a bespoke circulating tumor DNA (ctDNA) assay to detect molecular residual disease (MRD): The CORRECT-MRD I study
Srinivasan, G.
Hubert, A.
Purim, O.
Semenisty, V.
Lo, N.
Tsukada, Y.
Mondello, G.
Cubillo, A.
Subramaniam, S.
Palomares, M. R.
Baehner, R. F. L.
De Jong, F.
Kerr, D. J.
Yoshino, T.
ANNALS OF ONCOLOGY, 2024, 35 : S69 - S70
[13] CORRECT-MRD I: A clinical validation study to predict recurrence in stage II-III colorectal cancer (CRC) using a bespoke circulating tumor DNA (ctDNA) assay to detect molecular residual disease (MRD).
Tsukada, Yuichiro
Sagawa, Tamotsu
Srinivasan, Gopalakrishnan
Hubert, Ayala
Purim, Ofer
Semenisty, Valeriya
Lo, Nangi
Mondello, Giuseppe
Gracian, Antonio Cubillo
Marti, Tara
Subramaniam, Somasundaram
Palomares, Melanie R.
Baehner, Frederick
de Jong, Floris A.
Kerr, David James
Yoshino, Takayuki
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23_SUPPL) : TPS98 - TPS98
[14] Adjuvant chemotherapy (AC) for stage III colorectal cancer (CRC) in the elderly: An Irish experience.
Harrold, Emily
Greally, Megan
Peters, Niamh
Sui, Jane Sze Yin
McCaffrey, John
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[15] Eligibility of real-world patients with stage II/III colorectal cancer (CRC) in adjuvant chemotherapy (AC) trials
Batra, Atul
Kong, Shiying
Cheung, Winson Y.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[16] Use of circulating tumor DNA (ctDNA) to affect the adjuvant or post-adjuvant treatment of patients with stage III and high-risk stage II resected colon cancer: The ERASE-CRC project by GONO
Conca, Veronica
Vetere, Guglielmo
Moretto, Roberto
Lonardi, Sara
Antoniotti, Carlotta
Germani, Marco Maria
Pietrantonio, Filippo
Bittoni, Alessandro
Carullo, Martina
Salvatore, Lisa
Boccaccino, Alessandra
Ronzoni, Monica
Ricagno, Gianmarco
Toma, Ilaria
Cupini, Samanta
Latiano, Tiziana Pia
Arcangeli, Giuseppina
Masi, Gianluca
Fassan, Matteo
Cremolini, Chiara
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[17] REAL WORLD USE OF CIRCULATING TUMOR DNA (CTDNA) IN COLORECTAL CANCER (CRC): A TARGETED LITERATURE REVIEW (TLR)
Jones, G. S.
Bagga, S.
Sood, P.
Hariprasad, E.
Mangla, B.
Soni, P.
Sharma, N.
Jain, A.
Goswami, A.
Singh, P.
Kumar, S.
Kothari, S.
VALUE IN HEALTH, 2023, 26 (06) : S305 - S306
[18] Circulating tumor DNA (ctDNA) kinetics in colorectal cancer (CRC) treated with curative intent in the VICTORI study with an ultrasensitive MRD assay
Vasconcelos, Joao Paulo Solar
Titmuss, Emma
Navarro, Fabio
Abbott, Charles
Chia, Brendan
Topham, James T.
Ladua, Gale
Krishnan, Tharani
Hegebarth, Daniela
Lim, Howard J.
Gill, Karamjit
Gill, Sharlene
Brown, Carl J.
Ghuman, Amandeep
Meneghetti, Adam
Renouf, Daniel John
Schaeffer, David F.
Chen, Richard
Boyle, Sean Michael
Loree, Jonathan M.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[19] S-1 in colorectal cancer (CRC):: Interim results of an early phase II study.
Vermorken, J
Schöffski, P
Schellens, J
Roth, A
Duffaud, F
Bruntsch, U
Reinke, F
Wanders, J
De Boer, R
Fumoleau, P
ANNALS OF ONCOLOGY, 2000, 11 : 60 - 60
[20] TRACC: Tracking mutations in cell-free DNA to predict relapse in early colorectal cancer-A randomized study of circulating tumour DNA (ctDNA) guided adjuvant chemotherapy versus standard of care chemotherapy after curative surgery in patients with high risk stage II or stage III colorectal cancer (CRC).
Anandappa, Gayathri
Starling, Naureen
Peckitt, Clare
Bryant, Annette
Begum, Ruwaida
Carter, Paul
Hatt, Shelby
Khakoo, Shelize Sadrudin
Turner, Andrea
Kidd, Shannon
Duncan, Julie
Hobbis, Laura
Giorgakoudi, Kyriaki
Smalley, Michaela
Lowery, David
Wheatstone, Pete
Chau, Ian
Hubank, Michael
Cunningham, David
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →